Based on the findings, the company said it will not pursue regulatory approval of the drug for PPMS.
https://seekingalpha.com/news/4531292-sanofis-tolebrutinib-falls-short-in-phase-3-perseus-trial-for-primary-progressive-multiple-sclerosis
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.